✦ LIBER ✦

In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions

✍ Scribed by Thelingwani, R. S.; Zvada, S. P.; Dolgos, H.; Ungell, A.-L. B.; Masimirembwa, C. M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of CYP1A2 and CYP2E1 in the pentoxi

✍ Theresa C. Peterson; Marc R. Peterson; Philip A. Wornell; Matthew G. Blanchard; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Enzyme- and Transporter-Based Drug-Drug

✍ Pang, K. Sandy; Rodrigues, A. David; Peter, Raimund M. 📂 Article 📅 2009 🏛 Springer New York ⚖ 1002 KB

Identification of a novel chemical poten

✍ Takeshi Mitsui; Kazunori Hirayama; Shunsuke Aoki; Kaori Nishikawa; Kenko Uchida; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 476 KB

Fluoxetine- and Norfluoxetine-Mediated C

✍ Sager, J E; Lutz, J D; Foti, R S; Davis, C; Kunze, K L; Isoherranen, N 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 324 KB

Pharmacokinetic characterization of the

✍ Lee, Kyeong-Ryoon; Choi, Sung Heum; Song, Jin-Sook; Kwak, Eun-Young; Chae, Yoon- 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 742 KB

A poor metabolizer of both CYP2C19 and C

✍ Jornil, J.; Nielsen, T.S.; Rosendal, I.; Ahlner, J.; Zackrisson, A.L.; Boel, L.W 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 261 KB